Market Cap 151.10M
Revenue (ttm) 1.23M
Net Income (ttm) -28.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,326.83%
Debt to Equity Ratio -2.41
Volume 487,700
Avg Vol 945,522
Day's Range N/A - N/A
Shares Out 43.30M
Stochastic %K 35%
Beta 2.19
Analysts Sell
Price Target $34.67

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100,...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 254 6134
Address:
1201 N. Market Street, Suite 111, Wilmington, United States
Timberwolf1
Timberwolf1 Sep. 7 at 1:50 PM
$NRXP NRXPS VIALS: IF I am reading this PR correctly, it APPEARS NRXPs ketamine vials MAY have a Luer Lock 'TIP/connection' on them?? IF that is correct, and given the reported 'concerns' with the use of the Luer Lock 'system'?? Can see why the Luer Lock issues are now being pushed back onto NRXP. Anyone feel free to challenge this?? (could make for an easier connection/drawing of the contents) Also have to wonder if the million vials sitting on the shelves are all built this way. And the issue wouldn't appear to be with the tip itself, but the concerns over the potential issues with USING the luer lock system itself. NOTE: can see why NRXP is saying there is no issue with the TIPs on the vials, but thats not the 'issues' the fda appears concerned about. From the PR: The agency's sole request relates to packaging: attestation from the vial manufacturer that the luer lock tip is produced on the same lines and methods as those used in three FDA-approved ANDA products.
0 · Reply
Timberwolf1
Timberwolf1 Sep. 7 at 1:04 PM
$NRXP Luer Lock: wonder what NRXP is doing in response to the fda 'concerns', ie, what they REPORTEDLY submitted to show they are 'reliable' enough for NRXP to proceed with using them?? More info on what MIGHt be going on Current Solutions and Standards Best practices for legacy Luer locks: Hand-tighten, inspect visually, trace lines to source, and ensure fittings are dry before connection Quality control: Integrity testing per ASTM F2465-19a and ISO 10993-18:2017 to ensure durability, leak prevention, and biocompatibility Transition Outlook The medical industry is phasing out universal Luer locks in favor of ISO 80369 standards, but many facilities are still using legacy devices. Staff must remain vigilant during this transition Summary: Luer lock issues stem from its universal design, mechanical and material weaknesses, and misuse. The shift to application-specific connectors and strict handling protocols is the main mitigation strategy.
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Sep. 6 at 4:37 AM
$NRXP The man himself speaks, the bull with the sunglasses doesn't work for him however. Bet or no bet, he needs to follow through with the salary withholding if the current round with the FDA ends on a sour note. In the meantime lets stop with this nonsense.
0 · Reply
JavittMD
JavittMD Sep. 6 at 3:07 AM
$NRXP @jonny80s Jonny, your insistence that there is a stability problem is utterly unsupported by any facts or Company news. You rely on the fact that the September stability results won’t be read out for another few weeks to give you cover for non-stop fear mongering. Stability has been stable as a rock for 2.75 years and reported as such. Do you really think it’s falling off a cliff now? I will offer you the following bet: if we fail stability in September, I will forego a year’s salary. If this is all manipulation on your part, you leave this board and never return. ?Deal
1 · Reply
Dirk1969
Dirk1969 Sep. 5 at 9:01 PM
$NRXP https://www.rnz.co.nz/news/health/1256159/party-drug-mdma-gets-official-approval-as-ptsd-treatment
0 · Reply
Timberwolf1
Timberwolf1 Sep. 5 at 6:51 PM
$NRXP has anyone done a search to see WHY the fda appears to be challenging the luer lock system?? Got the below as a response, so maybe there is something going on that needs addressing?? MY QUESTION: Problems with Luer Lock Vials? Luer lock vials can cause serious safety issues due to misconnections, accidental separation, and procedural inconsistencies, even though they are designed to be secure The main problem is that the universal Luer lock design allows incompatible systems to be connected by mistake. Because all Luer locks look and feel the same, there is no built‑in prevention against connecting the wrong device. Accidental Separation, Leakage, and Air Embolism In summary: The core problems with Luer lock vials are the universal design’s inability to prevent misconnections, the risk of accidental disconnection, and potential for leaks or air embolisms. These issues are why the industry is moving toward standardized, non‑interchangeable connectors
0 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:52 PM
$NRXP And there are still many unanswered questions. Where are the 30+ clinics that were announced for 2025? Where is the projected $100 million in revenue? What happened to the submissions of the other NDAs? What is the current status of those applications? Questions upon questions, while long-term shareholders are still waiting for the results that have been promised for years.
1 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:51 PM
$NRXP Management also argues that only around 15–20% of ANDAs receive approval on the first attempt. My question is: after years of work and roughly $500 million in capital burned, why are we still part of the 80% that fail to achieve approval on the first attempt instead of the 20% that succeed? I have also not seen any announcement that management will give up salaries, bonuses, or other compensation when these targets are missed. Long-term shareholders continue to bear the consequences, while management compensation appears unaffected. We are now suddenly being told that we are in “Phase 2” of the approval process. Previously, I do not recall management communicating that this approval process consisted of different phases. To me, this looks like another communication tactic from the CEO. How many more phases, cycles, segments, stages, or percentages are long-term shareholders expected to go through before meaningful results are finally delivered?
0 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:49 PM
$NRXP Another Friday, another week with little to nothing achieved. Once again, short-term shareholders appear to benefit at the expense of long-term shareholders. For years, management has repeatedly stated that it is committed to creating value for loyal, long-term shareholders. Yet over the past several years, we have seen little evidence of that—other than dilution and profitable opportunities for institutions and short-term investors. For years, the CEO has mentioned that analysts see an average share price of around $35. The reality is very different: today we are sitting at approximately $3.45. Three years ago, JJ was complaining that the pre-split share price was around $0.30. Years later, after the reverse split, we are effectively still sitting at roughly $0.345 on a pre-split basis. So where exactly is the shareholder value that has been promised for years?
1 · Reply
chrisdacs
chrisdacs Sep. 4 at 3:39 PM
$NRXP one of these days ayahuasca will be the treatment for all negative mental maladies
0 · Reply
Latest News on NRXP
NRx Pharmaceuticals Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 24 days ago

NRx Pharmaceuticals Quarterly report: Q2 2026


NRx Pharmaceuticals Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 24 days ago

NRx Pharmaceuticals Earnings release: Q2 2026


NRx Pharmaceuticals Transcript: Status update

Aug 10, 2026, 8:30 AM EDT - 4 weeks ago

NRx Pharmaceuticals Transcript: Status update


NRx Pharmaceuticals issues response to Kadima statements

2026-06-25T20:15:31.000Z - 2 months ago

NRx Pharmaceuticals issues response to Kadima statements


Kadima Neuropsychiatry Institute alleges NRx breached contract

2026-06-24T17:25:15.000Z - 2 months ago

Kadima Neuropsychiatry Institute alleges NRx breached contract


NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

2026-06-03T15:17:33.000Z - 3 months ago

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50


NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026


NRx Pharmaceuticals Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Quarterly report: Q1 2026


NRx Pharmaceuticals Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings release: Q1 2026


NRx Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-13T10:11:36.000Z - 3 months ago

NRx Pharmaceuticals initiated with a Buy at Lucid Capital


NRx Pharmaceuticals gets FDA feedback on ketamine program

2026-04-22T11:48:51.000Z - 4 months ago

NRx Pharmaceuticals gets FDA feedback on ketamine program


NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 5 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025


NRx Pharmaceuticals Earnings release: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 5 months ago

NRx Pharmaceuticals Earnings release: Q4 2025


NRx Pharmaceuticals Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 5 months ago

NRx Pharmaceuticals Annual report: Q4 2025


NRx Pharmaceuticals Transcript: AGM 2026

Mar 23, 2026, 10:00 AM EDT - 5 months ago

NRx Pharmaceuticals Transcript: AGM 2026


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 6 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 23, 2026, 7:00 AM EST - 6 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2026, 7:00 AM EST - 6 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Registration statement: Registration Filing

Dec 12, 2025, 7:00 AM EST - 8 months ago

NRx Pharmaceuticals Registration statement: Registration Filing


NRx Pharmaceuticals Transcript: Study Update

Dec 2, 2025, 9:00 AM EST - 9 months ago

NRx Pharmaceuticals Transcript: Study Update


NRx Pharmaceuticals Press release: Study Update

Dec 2, 2025, 9:00 AM EST - 9 months ago

NRx Pharmaceuticals Press release: Study Update


NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025


NRx Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

NRx Pharmaceuticals Earnings release: Q3 2025


NRx Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

NRx Pharmaceuticals Quarterly report: Q3 2025


Timberwolf1
Timberwolf1 Sep. 7 at 1:50 PM
$NRXP NRXPS VIALS: IF I am reading this PR correctly, it APPEARS NRXPs ketamine vials MAY have a Luer Lock 'TIP/connection' on them?? IF that is correct, and given the reported 'concerns' with the use of the Luer Lock 'system'?? Can see why the Luer Lock issues are now being pushed back onto NRXP. Anyone feel free to challenge this?? (could make for an easier connection/drawing of the contents) Also have to wonder if the million vials sitting on the shelves are all built this way. And the issue wouldn't appear to be with the tip itself, but the concerns over the potential issues with USING the luer lock system itself. NOTE: can see why NRXP is saying there is no issue with the TIPs on the vials, but thats not the 'issues' the fda appears concerned about. From the PR: The agency's sole request relates to packaging: attestation from the vial manufacturer that the luer lock tip is produced on the same lines and methods as those used in three FDA-approved ANDA products.
0 · Reply
Timberwolf1
Timberwolf1 Sep. 7 at 1:04 PM
$NRXP Luer Lock: wonder what NRXP is doing in response to the fda 'concerns', ie, what they REPORTEDLY submitted to show they are 'reliable' enough for NRXP to proceed with using them?? More info on what MIGHt be going on Current Solutions and Standards Best practices for legacy Luer locks: Hand-tighten, inspect visually, trace lines to source, and ensure fittings are dry before connection Quality control: Integrity testing per ASTM F2465-19a and ISO 10993-18:2017 to ensure durability, leak prevention, and biocompatibility Transition Outlook The medical industry is phasing out universal Luer locks in favor of ISO 80369 standards, but many facilities are still using legacy devices. Staff must remain vigilant during this transition Summary: Luer lock issues stem from its universal design, mechanical and material weaknesses, and misuse. The shift to application-specific connectors and strict handling protocols is the main mitigation strategy.
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Sep. 6 at 4:37 AM
$NRXP The man himself speaks, the bull with the sunglasses doesn't work for him however. Bet or no bet, he needs to follow through with the salary withholding if the current round with the FDA ends on a sour note. In the meantime lets stop with this nonsense.
0 · Reply
JavittMD
JavittMD Sep. 6 at 3:07 AM
$NRXP @jonny80s Jonny, your insistence that there is a stability problem is utterly unsupported by any facts or Company news. You rely on the fact that the September stability results won’t be read out for another few weeks to give you cover for non-stop fear mongering. Stability has been stable as a rock for 2.75 years and reported as such. Do you really think it’s falling off a cliff now? I will offer you the following bet: if we fail stability in September, I will forego a year’s salary. If this is all manipulation on your part, you leave this board and never return. ?Deal
1 · Reply
Dirk1969
Dirk1969 Sep. 5 at 9:01 PM
$NRXP https://www.rnz.co.nz/news/health/1256159/party-drug-mdma-gets-official-approval-as-ptsd-treatment
0 · Reply
Timberwolf1
Timberwolf1 Sep. 5 at 6:51 PM
$NRXP has anyone done a search to see WHY the fda appears to be challenging the luer lock system?? Got the below as a response, so maybe there is something going on that needs addressing?? MY QUESTION: Problems with Luer Lock Vials? Luer lock vials can cause serious safety issues due to misconnections, accidental separation, and procedural inconsistencies, even though they are designed to be secure The main problem is that the universal Luer lock design allows incompatible systems to be connected by mistake. Because all Luer locks look and feel the same, there is no built‑in prevention against connecting the wrong device. Accidental Separation, Leakage, and Air Embolism In summary: The core problems with Luer lock vials are the universal design’s inability to prevent misconnections, the risk of accidental disconnection, and potential for leaks or air embolisms. These issues are why the industry is moving toward standardized, non‑interchangeable connectors
0 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:52 PM
$NRXP And there are still many unanswered questions. Where are the 30+ clinics that were announced for 2025? Where is the projected $100 million in revenue? What happened to the submissions of the other NDAs? What is the current status of those applications? Questions upon questions, while long-term shareholders are still waiting for the results that have been promised for years.
1 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:51 PM
$NRXP Management also argues that only around 15–20% of ANDAs receive approval on the first attempt. My question is: after years of work and roughly $500 million in capital burned, why are we still part of the 80% that fail to achieve approval on the first attempt instead of the 20% that succeed? I have also not seen any announcement that management will give up salaries, bonuses, or other compensation when these targets are missed. Long-term shareholders continue to bear the consequences, while management compensation appears unaffected. We are now suddenly being told that we are in “Phase 2” of the approval process. Previously, I do not recall management communicating that this approval process consisted of different phases. To me, this looks like another communication tactic from the CEO. How many more phases, cycles, segments, stages, or percentages are long-term shareholders expected to go through before meaningful results are finally delivered?
0 · Reply
fuctonfauci
fuctonfauci Sep. 4 at 3:49 PM
$NRXP Another Friday, another week with little to nothing achieved. Once again, short-term shareholders appear to benefit at the expense of long-term shareholders. For years, management has repeatedly stated that it is committed to creating value for loyal, long-term shareholders. Yet over the past several years, we have seen little evidence of that—other than dilution and profitable opportunities for institutions and short-term investors. For years, the CEO has mentioned that analysts see an average share price of around $35. The reality is very different: today we are sitting at approximately $3.45. Three years ago, JJ was complaining that the pre-split share price was around $0.30. Years later, after the reverse split, we are effectively still sitting at roughly $0.345 on a pre-split basis. So where exactly is the shareholder value that has been promised for years?
1 · Reply
chrisdacs
chrisdacs Sep. 4 at 3:39 PM
$NRXP one of these days ayahuasca will be the treatment for all negative mental maladies
0 · Reply
Dirk1969
Dirk1969 Sep. 4 at 3:08 PM
$NRXP Second country in the world: New Zealand approves MDMA treatment for severe PTSD. New Zealand's medicines authority has approved the use of MDMA for the treatment of severe PTSD. In 2023, Australia became the first country in the world to approve the use of psychedelics for treating PTSD and treatment-resistant depression.
1 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Sep. 4 at 4:30 AM
$NRXP We'll call a spade a spade as mom used to say--no doubt the mfg. submitted the info asap because they want to make money. While we are waiting other companies that will be relying on NRXP are doing damage control to get ready for a big change. They have to or else they are jeopardizing their livelihood. So in that sense the delay is priming the pumps. We'll see. With a little help Javitt should be able to get through.
0 · Reply
Tide16
Tide16 Sep. 3 at 12:21 PM
0 · Reply
DavidBG
DavidBG Sep. 3 at 12:04 PM
$NRXP There doesn't seem to be any information to support the talk of imminent FDA news. DARPA news seems likely to drop first, and it's also an important catalyst, both in terms of long-term value creation and in terms of market participants who will buy as a result.
2 · Reply
uwmctothemoon19191
uwmctothemoon19191 Sep. 3 at 9:08 AM
$NRXP 🤞
0 · Reply
Braxton14
Braxton14 Sep. 3 at 9:07 AM
$NRXP FDA deal today!
2 · Reply
dcajic2
dcajic2 Sep. 2 at 7:54 PM
$NRXP One needs to be patient. If you can’t be patient with a stock like NRXP you should not be reading on your own . They have a minor deficiency. Fda approval will happen. fDA Takes their time . Should know something before end of year.
1 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Sep. 2 at 5:48 PM
$NRXP Right now, we are locked inside of a pain amplifier. Patience is waning to the point of wearing thin... yawn, so it's easy to understand the bearish sentiment.
1 · Reply
gus_trades
gus_trades Sep. 2 at 3:48 PM
$NRXP there is literally dog shit on the volume today and even though the share price has dropped to 3.40 the POC for todays Volume Profile is still at 3.50. the fact that the the 10Y Treasury Yield is at an almost 16 year high, (it hit this rate in 2023 but before that was 2007-2008) but were at the textbook market conditions for derisking and institutional shareholders havent dumped this stock into oblivion tells me more than i need to know. (it is considered a risk on or Neutral for other sectors but not for clinical trial stage pre revenue bio tech stocks. My PLUG Power and TNYA stocks are getting ravaged right now but my Chevron are crushing it) https://feargreedmeter.com/ https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-09-02-2026 the share price dip this morning is purely retail. taking profit/cutting losses to invest elsewhere everyone who can read the market is in a holding pattern for NRXP. you cant just read the tape and the SEC filings, you need to look at the overall market.
0 · Reply
StevenL85
StevenL85 Sep. 2 at 3:22 PM
$NRXP buy the time we have some progress a new offering is on the horizon. 😂
0 · Reply
Ketasniffer
Ketasniffer Sep. 2 at 2:16 PM
$NRXP have fun in Pattaya Thailand @TheRealBomb !!!
0 · Reply
jonny80s
jonny80s Sep. 2 at 12:43 PM
$NRXP I see this playing out as follows: Ketafree fails the 3 yr stability test. The news breaks. NRXP ends up needing to submit a major amendment which again extends the review. Anson/whoever built the massive short position over the last 6 months covers. All speculation of course. Just a gut feeling based on what I’ve seen from Javitt before. There is a reason why Javitt went dark at the 15 month point for stability. Thoughts?
4 · Reply